Previous 10 |
Gainers: Arcadia Biosciences (NASDAQ: RKDA ) +83% . Horizon Pharma Public (NASDAQ: HZNP ) +30% . J. C. Penney Company (NYSE: JCP ) +27% . Sequential Brands Group (NASDAQ: SQBG ) +28% . Triple-S Management (NYSE: GTS ) +25% . TG Therapeutics (NASDAQ: TGTX ) +21% . T2 Biosystems ...
SAN DIEGO , Feb. 28, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, ...
SAN DIEGO , Feb. 19, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today a reverse split of its com...
SAN DIEGO , Feb. 14, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today...
SAN DIEGO , Jan. 29, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced an agreement with PoC...
Quick Take Guardant Health ( GH ) intends to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm provides genomic cancer testing services from a single blood draw. GH is growing at an accelerating rate, has ample resources and co...
Redwood City, CA-based Guardant Health ( GH ) has filed a prospectus for a $100M IPO. More news on: Guardant Health, TrovaGene, Inc., Roche Holding Ltd ADR, Healthcare stocks news, IPOs, Read more ...
SAN DIEGO , Sept. 5, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs for the treatment of leukemias, lymphomas and solid tumor cancers, today announced it has developed a me...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...